Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A

K. Reckamp; Z. Song; S. Gettinger; E. P. Mitchell; J. J. Wright; J. A. Moscow; R. J. Gray; V. Wang; L. M. McShane; L. V. Rubinstein; D. R. Patton; P. M. Williams; S. R. Hamilton; B. A. Conley; C. L. Arteaga; L. N. Harris; P. J. O'Dwyer; A. P. Chen; K. T. Flaherty

doi:10.1016/S0959-8049(22)01023-1

Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A

K. Reckamp, Z. Song, S. Gettinger, E. P. Mitchell, J. J. Wright, J. A. Moscow, R. J. Gray, V. Wang, L. M. McShane, L. V. Rubinstein, D. R. Patton, P. M. Williams, S. R. Hamilton, B. A. Conley, C. L. Arteaga, L. N. Harris, P. J. O'Dwyer, A. P. Chen, K. T. Flaherty

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	S84-S85
Journal	European Journal of Cancer
Volume	174
DOIs	https://doi.org/10.1016/S0959-8049(22)01023-1
State	Published - Oct 2022
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/S0959-8049(22)01023-1

Cite this

Reckamp, K., Song, Z., Gettinger, S., Mitchell, E. P., Wright, J. J., Moscow, J. A., Gray, R. J., Wang, V., McShane, L. M., Rubinstein, L. V., Patton, D. R., Williams, P. M., Hamilton, S. R., Conley, B. A., Arteaga, C. L., Harris, L. N., O'Dwyer, P. J., Chen, A. P., & Flaherty, K. T. (2022). Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A. European Journal of Cancer, 174, S84-S85. https://doi.org/10.1016/S0959-8049(22)01023-1

Reckamp, K, Song, Z, Gettinger, S, Mitchell, EP, Wright, JJ, Moscow, JA, Gray, RJ, Wang, V, McShane, LM, Rubinstein, LV, Patton, DR, Williams, PM, Hamilton, SR, Conley, BA, Arteaga, CL, Harris, LN, O'Dwyer, PJ, Chen, AP & Flaherty, KT 2022, 'Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A', European Journal of Cancer, vol. 174, pp. S84-S85. https://doi.org/10.1016/S0959-8049(22)01023-1

@article{d1f478eb12dd4bfa94a88ec38aef20ae,

title = "Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A",

author = "K. Reckamp and Z. Song and S. Gettinger and Mitchell, {E. P.} and Wright, {J. J.} and Moscow, {J. A.} and Gray, {R. J.} and V. Wang and McShane, {L. M.} and Rubinstein, {L. V.} and Patton, {D. R.} and Williams, {P. M.} and Hamilton, {S. R.} and Conley, {B. A.} and Arteaga, {C. L.} and Harris, {L. N.} and O'Dwyer, {P. J.} and Chen, {A. P.} and Flaherty, {K. T.}",

note = "Funding Information: This study was coordinated by the ECOG-ACRIN Cancer Research Group (Peter J. O{\textquoteright}Dwyer, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs) and supported by the National Cancer Institute of the National Institutes of Health under award numbers: U10CA180820, U10CA180794, UG1CA233302, UG1CA233180, UG1CA233341, and UG1CA233337. Funding Information: Carlos L. Arteaga, receives or has received research grants from Pfizer, Lilly and Takeda holds minor stock options in Provista serves or has served in an advisory role to Novartis, Merck, Lilly, Daiichi Sankyo, Taiho Oncology, OrigiMed, Puma Biotechnology, Immunomedics, AstraZeneca, Arvinas, and Sanofi and reports scientific advisory board remuneration from the Susan G. Komen Foundation.",

year = "2022",

month = oct,

doi = "10.1016/S0959-8049(22)01023-1",

language = "English (US)",

volume = "174",

pages = "S84--S85",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer

T2 - results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A

AU - Reckamp, K.

AU - Song, Z.

AU - Gettinger, S.

AU - Mitchell, E. P.

AU - Wright, J. J.

AU - Moscow, J. A.

AU - Gray, R. J.

AU - Wang, V.

AU - McShane, L. M.

AU - Rubinstein, L. V.

AU - Patton, D. R.

AU - Williams, P. M.

AU - Hamilton, S. R.

AU - Conley, B. A.

AU - Arteaga, C. L.

AU - Harris, L. N.

AU - O'Dwyer, P. J.

AU - Chen, A. P.

AU - Flaherty, K. T.

N1 - Funding Information: This study was coordinated by the ECOG-ACRIN Cancer Research Group (Peter J. O’Dwyer, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs) and supported by the National Cancer Institute of the National Institutes of Health under award numbers: U10CA180820, U10CA180794, UG1CA233302, UG1CA233180, UG1CA233341, and UG1CA233337. Funding Information: Carlos L. Arteaga, receives or has received research grants from Pfizer, Lilly and Takeda holds minor stock options in Provista serves or has served in an advisory role to Novartis, Merck, Lilly, Daiichi Sankyo, Taiho Oncology, OrigiMed, Puma Biotechnology, Immunomedics, AstraZeneca, Arvinas, and Sanofi and reports scientific advisory board remuneration from the Susan G. Komen Foundation.

PY - 2022/10

Y1 - 2022/10

UR - http://www.scopus.com/inward/record.url?scp=85140472677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85140472677&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(22)01023-1

DO - 10.1016/S0959-8049(22)01023-1

M3 - Article

AN - SCOPUS:85140472677

SN - 0959-8049

VL - 174

SP - S84-S85

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this